NASDAQ · Biotechnology

Aprea Therapeutics, Inc. (APRE) Stock

$0.60 +8.28% NASDAQ: APRE Healthcare

Valuation

MetricValue
Price$0.60
Market Cap$7.48M
P/E Ratio-0.64
P/B Ratio0.97
P/S Ratio51.14
EPS (TTM)$0.00
52-Week High$1.69
52-Week Low$0.55
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-46.72%
ROA-29.10%
ROCE-33.73%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio5.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$1.0M$2.0M$0
Operating Profit$-37.0M$-113.0M$-15.0M$-14.0M$-13.0M
Net Profit$-37.0M$-113.0M$-14.0M$-13.0M$-13.0M
EPS$-34.88$-1359.79$-3.95$-2.35$-1.93
Op Margin——-2652.8%-953.0%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$57.0M$30.0M$23.0M$24.0M$16.0M
Total Liabilities$7.0M$5.0M$4.0M$5.0M$3.0M
Cash$53.0M$29.0M$22.0M$23.0M$15.0M
Borrowings$0$0$0$0$0

Latest News

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors GlobeNewswire · Jun 1, 2026 Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update GlobeNewswire · May 13, 2026 Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls The Fly · May 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-38.0M$-25.0M$-12.0M$-14.0M$-13.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$-1.0M$-1.0M$0
Net Cash Flow$-36.0M$-24.0M$-7.0M$1.0M$-8.0M
Free Cash Flow$-38.0M$-25.0M$-12.0M$-14.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA2.66
FCF Yield-141.57%
Quick Ratio13.55
Interest Coverage0.00
Return 1Y-57.19%
Return 3Y-77.71%
Return 5Y-99.31%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXPAcurx Pharmaceuticals, Inc. $1.27 +1.60% -0.36 $5.46M 0.00%
ADILAdial Pharmaceuticals, Inc $3.90 -1.76% -0.26 $10.24M 0.00%
APVOAptevo Therapeutics Inc. $1.79 -0.56% -0.01 $3.91M 0.00%
BCDABioCardia, Inc. $1.04 -1.89% -1.54 $15.48M 0.00%
CELZCreative Medical Technology Holdings, Inc. $0.84 -2.55% -0.47 $2.16M 0.00%

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is led by CEO Oren Gilad, employs 8 people, headquartered in US, publicly traded since 2019.

Aprea Therapeutics, Inc. (APRE) stock trades at $0.60 with a market capitalization of $7.48M. The stock is valued at a price-to-earnings (P/E) ratio of -0.64, price-to-book of 0.97, price-to-sales of 51.14. Over the past 52 weeks the stock has ranged between $0.55 and $1.69, and currently trades 64.5% below its 52-week high.

On profitability, Aprea Therapeutics, Inc. generates a return on equity (ROE) of -46.72%, return on capital employed of -33.73%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides